These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1121004)

  • 21. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide.
    Ludeman SM; Boyd VL; Regan JB; Gallo KA; Zon G; Ishii K
    J Med Chem; 1986 May; 29(5):716-27. PubMed ID: 3701785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antitumor activity of adriamycin].
    Kitaura K; Watanabe Y; Ishihara Y; Takahira H
    Jpn J Antibiot; 1972 Apr; 25(2):65-71. PubMed ID: 4341940
    [No Abstract]   [Full Text] [Related]  

  • 23. Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
    Misiura K; Kinas RW; Stec WJ; Kusnierczyk H; Radzikowski C; Sonoda A
    J Med Chem; 1988 Jan; 31(1):226-30. PubMed ID: 3336021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
    Voelcker G; Haeglsperger R
    Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of reactive metabolite-analogues of cyclophosphamide for comparisons of NMR kinetic parameters and anticancer screening data.
    Ludeman SM; Boyd VL; Regan JB; Gallo KA; Zon G; Ishii K
    Drugs Exp Clin Res; 1986; 12(6-7):527-32. PubMed ID: 3743371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and structure-activity relationships of pre-activated analogs of cyclophosphamide (NSC-26271).
    Montgomery JA; Struck RF
    Cancer Treat Rep; 1976 Apr; 60(4):381-93. PubMed ID: 945126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of neutrophil chemotaxis by 4-hydroxycyclophosphamide.
    Gilbert DN; Starr P; Eubanks N
    Cancer Res; 1977 Feb; 37(2):456-9. PubMed ID: 832269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.
    Gerhartz HH; Liss E; Schmidt H
    J Cancer Res Clin Oncol; 1979 Jul; 94(3):257-63. PubMed ID: 479265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effects of bis(3-methylsulfonyloxypropyl)-amine toluenesulfonate (864-T) with 6-mercaptopurine and other antitumor agents.
    Imamura H; Ikegami K; Okumoto T
    Gan; 1973 Oct; 64(5):427-31. PubMed ID: 4358730
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis and antitumor properties of activated cyclophosphamide analogues.
    Borch RF; Canute GW
    J Med Chem; 1991 Oct; 34(10):3044-52. PubMed ID: 1920355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
    Teicher BA; Holden SA; Goff DA; Wright JE; Tretyakov O; Ayash LJ
    Cancer Chemother Pharmacol; 1996; 38(6):553-60. PubMed ID: 8823498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and absolute configuration of the optically active forms of 2-(bis(2-chloroethyl)amino)-4-methyltetrahydro-2h-1,3,2-oxazaphosphorine 2-oxide (4-methylcyclophosphamide).
    Kinas R; Pankiewicz K; Stec WJ
    J Org Chem; 1977 Apr; 42(9):1650-2. PubMed ID: 853328
    [No Abstract]   [Full Text] [Related]  

  • 33. Does acrolein contribute to the cytotoxicity of cyclophosphamide?
    Wrabetz E; Peter G; Hohorst HJ
    J Cancer Res Clin Oncol; 1980; 98(2):119-26. PubMed ID: 7217177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of the protector thiol L-cystein on the toxic and therapeutic responses of stabilized "activated" cyclophosphamide (4-(S-ethanol)-sulfido-cyclophosphamide).
    Voelcker G; Laber P; Rockinger H; Wientzek C; Hohorst HJ
    Invest New Drugs; 1984; 2(2):253-9. PubMed ID: 6469518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and antitumor activity of cyclophosphamide analogues. 3. Preparation, molecular structure determination and anticancer screening of racemic cis- and trans-4-phenylcyclophosphamide.
    Boyd VL; Zon G; Himes VL; Stalick JK; Mighell AD; Secor HV
    J Med Chem; 1980 Apr; 23(4):372-5. PubMed ID: 7381836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
    Takamizawa A; Matsumoto S; Iwata T; Makino I; Yamaguchi K; Uchida N; Kasai H; Shiratori O; Takase S
    J Med Chem; 1978 Feb; 21(2):208-14. PubMed ID: 621716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.
    Peter G; Hohorst HJ
    Cancer Chemother Pharmacol; 1979; 3(3):181-8. PubMed ID: 527208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro.
    Erickson LC; Ramonas LM; Zaharko DS; Kohn KW
    Cancer Res; 1980 Nov; 40(11):4216-20. PubMed ID: 7471062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
    Low JE; Borch RF; Sladek NE
    Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia.
    Hilton J
    Cancer Res; 1984 Nov; 44(11):5156-60. PubMed ID: 6488175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.